Submitted by web@researchtop... on Tue, 03/03/2020 - 16:55
CME Test
CME information and disclosures
Select publications
Video program
Listen to streaming audio
right from your computer
Download program
to your desktop
Subscribe to podcast
to have this and future issues delivered to your iTunes library
Audio Highlights
Interview with Harold J Burstein, MD, PhD
Topic 1:
Use of genomic classifiers to inform therapeutic decision-making for ER-positive localized breast cancer
Topic 2:
Prognostic and/or predictive utility of the various genomic assays for patients with node-negative and node-positive early breast cancer
Topic 3:
Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized breast cancer
Topic 4:
Effects of prolonging adjuvant aromatase inhibitor therapy beyond 5 years on recurrence and cause-specific mortality
Topic 5:
NSABP-B-42: Ten-year results of extended adjuvant endocrine therapy with letrozole for postmenopausal women with ER-positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor (AI)
Topic 6:
Optimizing the use of CDK4/6 inhibitors in the management of ER-positive metastatic breast cancer (mBC); overall survival findings and mechanisms of resistance
Topic 7:
Management of de novo ER-positive, HER2-negative mBC
Topic 8:
Choice of endocrine therapy partner for patients with de novo ER-positive, HER2-negative mBC
Topic 9:
Approach for patients with mBC and disease progression on an AI
Topic 10:
Selection and sequencing of CDK4/6 inhibitors in mBC; comparison of side-effect profiles
Topic 11:
Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC
Topic 12:
Results of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with ER-positive, HER2-negative advanced BC with or without a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval for breast cancer with a PIK3CA mutation and current clinical role
Topic 13:
Spectrum, frequency and severity of toxicities observed with alpelisib
Topic 14:
Clinical experience with everolimus in mBC; potential for its use after disease progression on a CDK4/6 inhibitor
Topic 15:
Biologic rationale for evaluation of the Bcl-2 inhibitor venetoclax in ER-positive mBC
Topic 16:
Overview of the novel HER2-directed agents trastuzumab deruxtecan and tucatinib for HER2-positive mBC
Topic 17:
Dual targeted approach for patients with ER/PR-positive, HER2-positive mBC
Topic 18:
Investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway
Topic 19:
Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role
Topic 20:
Perspectives of Dr Burstein and Dr Love on the passing and legacy of the breast cancer revolutionary Dr Bernard Fisher
Topic 21:
Advances in the adjuvant treatment of HER2-positive and triple-negative breast cancer
FACULTY
Harold J Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida